Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Early Dose Escalation Using Extended-Release Tacrolimus (Envarsus XR®) to Reduce Acute Rejection and Donor Specific Antibodies in African American Renal Transplant Recipients

NCT04665310 is registered in ClinicalTrials.gov with The Methodist Hospital Research Institute as lead sponsor.

NCT NCT04665310
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04665310 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Early Dose Escalation Using Extended-Release Tacrolimus (Envarsus XR®) to Reduce Acute Rejection and Donor Specific Antibodies in African American Renal Transplant Recipients
Lead sponsor
The Methodist Hospital Research Institute
Phase
Phase 4
Overall status
Active, not recruiting
Start date
September 1, 2018
Completion date
October 31, 2025
Enrollment
46 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute rejection of renal transplant, donor specific antibodies, kidney disease, end-stage